Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

Core Viewpoint - Rhythm Pharmaceuticals has received FDA approval for an expanded indication of IMCIVREE (setmelanotide) to treat acquired hypothalamic obesity, marking it as the first and only FDA-approved therapy for this condition [7][9]. Company Overview - Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, with its lead product IMCIVREE designed to treat hyperphagia and severe obesity [16]. - The company estimates approximately 10,000 individuals in the U.S. are affected by acquired hypothalamic obesity [9][15]. Product Details - IMCIVREE is indicated for reducing excess body weight and maintaining long-term weight reduction in adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity [17]. - The approval is based on the Phase 3 TRANSCEND trial, which demonstrated a statistically significant -18.4% placebo-adjusted reduction in body mass index (BMI) [6][10]. Clinical Trial Results - In the TRANSCEND trial, participants on setmelanotide achieved a -15.8% reduction in BMI compared to a +2.6% increase in the placebo group at 52 weeks [10]. - Setmelanotide was generally well tolerated, with common adverse events including skin hyperpigmentation, nausea, vomiting, and headache [10][27]. Market Implications - The approval of IMCIVREE addresses a critical unmet need for patients with acquired hypothalamic obesity, providing a targeted therapy that addresses the underlying biology of the disease [9][10]. - The company is committed to supporting patient access to IMCIVREE through programs like Rhythm InTune, which offers educational support and assistance with insurance navigation [12].